GeneDx Holdings Corp.

Equities

WGS

US81663L2007

Healthcare Facilities & Services

Market Closed - Nasdaq 04:00:00 2024-05-01 pm EDT 5-day change 1st Jan Change
20.92 USD +22.55% Intraday chart for GeneDx Holdings Corp. +76.99% +660.73%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Health Care Flat Amid Mixed Earnings -- Health Care Roundup DJ
Sector Update: Health Care Stocks Mixed Late Afternoon MT
Top Midday Gainers MT
TD Cowen Adjusts GeneDx Holdings' Price Target to $24 From $14, Keeps Buy Rating MT
BTIG Adjusts GeneDx Holdings' Price Target to $19 From $15, Keeps Buy Rating MT
Transcript : GeneDx Holdings Corp., Q1 2024 Earnings Call, Apr 29, 2024
GeneDx Holdings Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
GeneDx Holdings Corp. Updates Earnings Guidance for the Year 2024 CI
Genedx Announces Partnership with Komodo Health to Expand Access to World?S Largest Rare Disease Dataset CI
Goldman Sachs Adjusts GeneDx Holdings Price Target to $11 From $6, Maintains Neutral Rating MT
Health Care Down on a Mixed Growth View -- Health Care Roundup DJ
Earnings Flash (WGS) GENEDX HOLDINGS Posts Q4 Revenue $57.4M MT
Transcript : GeneDx Holdings Corp., Q4 2023 Earnings Call, Feb 20, 2024
GeneDx Holdings Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
GeneDx Holdings Corp. Provides Earnings Guidance for the Full Year of 2024 CI
GeneDx Shares Gain After Preliminary Q4 Revenue Outlook MT
Genedx Holdings Corp. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 CI
GeneDx Holdings Corp.(NasdaqGS:WGS) dropped from S&P Global BMI Index CI
Genedx Holdings Insider Bought Shares Worth $161,368, According to a Recent SEC Filing MT
Genedx Holdings Insider Sold Shares Worth $1,140,027, According to a Recent SEC Filing MT
Transcript : GeneDx Holdings Corp., Q3 2023 Earnings Call, Oct 30, 2023
Earnings Flash (WGS) GENEDX HOLDINGS Reports Q3 Revenue $53.3M, vs. Street Est of $52.4M MT
GeneDx Holdings Corp. Updates Revenue Guidance for the Full Year 2023 CI
GeneDx Holdings Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Genedx Holdings Corp. Announces Executive Appointments CI
Chart GeneDx Holdings Corp.
More charts
GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Company's segments are GeneDx inclusive of Legacy GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. GeneDx utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. GeneDx provides a variety of genetic diagnostic tests, screening solutions, and information. The Legacy Sema4 diagnostics segment provides reproductive and women's health and somatic oncology diagnostic testing and screening products.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
20.92 USD
Average target price
15.25 USD
Spread / Average Target
-27.10%
Consensus
  1. Stock Market
  2. Equities
  3. WGS Stock
  4. News GeneDx Holdings Corp.
  5. BTIG Cuts GeneDx Holdings' Price Target to $1.25 From $2, Maintains Buy Rating